George Clinical

SYDNEY, July 27, 2023 (GLOBE NEWSWIRE) -- George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the…

SYDNEY, June 27, 2023 (GLOBE NEWSWIRE) -- George Clinical and EPS Corporation (EPS), a global CRO based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian…

<!-- Name:DistributionId Value:8831407 --> <!-- Name:EnableQuoteCarouselOnPnr Value:True --> <!-- Name:IcbCode Value: -->…

SYDNEY, Dec. 09, 2022 (GLOBE NEWSWIRE) -- George Clinical announces that it has entered into a sale agreement with Hillhouse, a global investment firm with deep experience in partnering with and supporting healthcare businesses. The…

OVERLAND PARK, KS., March 01, 2022 (GLOBE NEWSWIRE) -- George Clinical announces the expansion of its renal scientific leadership into Latin America with the addition of subject matter expert Hernán Trimarchi, MD, PHD, FACP, FASN.…

OVERLAND PARK, KS., Nov. 12, 2021 (GLOBE NEWSWIRE) -- New kidney and metabolic research involving George Clinical teams and scientific leaders has received global attention during the 2021 American Society of Nephrology’s Kidney Week…

SYDNEY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Graham Birrell, PhD, MBA, a researcher and neuropharmacologist with significant clinical research experience in the EU and Asia-Pacific region has joined George Clinical, a global…

OVERLAND PARK, KS, July 29, 2021 (GLOBE NEWSWIRE) -- The findings of DARE-19, a double-blind, placebo-controlled Phase III trial examining Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19, have been…